Ethics of cancer gene transfer clinical research

Methods in Molecular Biology

Volumn 542, Issue , 2009, Pages 423-445

  Kimmelman, Jonathan ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cancer; correlative studies; ethics; gene transfer; informed consent; phase 1; risk; uncertainty; value

Indexed keywords

CLINICAL TRIAL; ETHICS; GENE THERAPY; GENE TRANSFER; HUMAN; MEDICAL RESEARCH; NEOPLASM; PUBLIC OPINION; REVIEW;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; NEOPLASMS; PUBLIC OPINION;

EID: 67650312163     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-561-9_23     Document Type: Review

References (108)

1. The National Commission for the Protection of Human Subjects of Biomedical and Behavioural Research (1979) The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research.Department of Health, Education, and Welfare, ed).
2. Medical Research Council of Canada (2003) Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans.
3. World Medical Association (1964) Declaration of Helsinki.
4. Rainsbury , J. M.2000) Biotechnology on the RAC-FDA/NIH regulation of human gene therapy Food Drug Law J 55 , 575-600
5. King , N. M.2002) RAC oversight of gene transfer research: a model worth extending? J. Law. Med. Ethics 30 , 381-389
6. Cornetta , K. , and Smith , F.O.2002) Regulatory issues for clinical gene therapy trials Hum. Gene Ther 13 , 1143-1149
7. Holzen, U W., and Swisher, S.G.2007) In Cancer Drug Discovery and Development: Gene Therapy for Cancer (Hunt, K.K., et al., eds), Humana Press, Totowa, NJ.
8. Wallace , J.2000) Humane endpoints and cancer research ILAR J 41 , 87-93
9. Klein , H. J. , and Bayne , K. A.2007) Establishing a culture of care, conscience, and responsibility: addressing the improvement of scientific discovery and animal welfare through science-based performance standards ILAR J 48 , 3-11
10. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) (1998) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition) Br. J. Cancer 77 , 1-10
11. DeGrazia , D.1996) Taking Animanls Seriously: Mental Life and Moral Status Cambridge University Press , New York
12. Daugherty , C. K.1999) Ethical issues in the development of new agents Invest. New Drugs 17 , 145-153
13. Daugherty , C. K. , et al.2000) Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 adVanced cancer patients IRB. 22 , 6-14
14. Jayson , G. , and Harris , J.2006) How participants in cancer trials are chosen: ethics and conflicting interests Nat. Rev. Cancer 6 , 330-336
15. Daugherty , C. K.2000) Informed consent, the cancer patient, and phase I clinical trials Cancer Treat. Res 102 , 77-89
16. Grunwald , H. W.2007) Ethical and Design Issues of Phase I Clinical Trials in Cancer Patients Cancer Invest 25 , 124-126
17. Djulbegovic , B.2007) Articulating and responding to uncertainties in clinical research J. Med. Philos 32 , 79-98
18. Kimmelman , J.2005) Recent developments in gene transfer: risk and ethics BMJ 330 , 79-82
19. Morral , N. , et al.2002) Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons Hum. Gene Ther 13 , 143-154
20. Halpern , S. D. , et al.2002) The continuing unethical conduct of underpowered clinical trials JAMA 288 , 358-362
21. U.S. Food and Drug Administration (2007) Drugs for Human Use: Investigational New Drug Application 21CFR312.21(a).Department of Health and Human Services, ed).
22. DiMasi , J.A. , and Grabowski , H.G.2007) Economics of new oncology drug development J. Clin. Oncol 25 , 209-216
23. Search GEMCRIS using Medical condition "cancer"; December 5, 2007. Note that GEMCRIS is not a complete listing of all GT cancer studies (protocols of studies pursued outside of institutions receiving NIH funds are not always submitted to OBA); note also that not all studies registered with OBA are actually initiated or completed.
24. Wiley. Searched December 5, 2007. For purposes of calculation, phase 1-2 studies were counted as phase 1; phase 2-3 studies were counted as phase 2.
25. Orkin, S.H., and Motulsky, A.G.1995) Report and Recommendations of the Panel to Asses the NIH Investment in Research on Gene Therapy.National Institutes of Health - Office of Biotechnology Activities, ed).
26. Albelda , S.M. , and Sterman , D.H.2004) TNFerade to the rescue? Guidelines for evaluating phase I cancer gene transfer trials J. Clin. Oncol 22 , 577-579
27. Freedman , B.1987) Equipoise and the ethics of clinical research N. Engl. J. Med 317 , 141-145
28. London , A.J.2007) Clinical Equipoise: Foundational Requirement or Fundamental Error? In The Oxford Handbook of Bioethics ( Steinbock , B. , ed), Oxford University Press , New York
29. Schou , K. C. , and Hewison , J.1999) Experiencing Cancer: Quality of Life in Treatment Open University Press , Buckingham
30. Dirnagl , U.2006) Bench to bedside: the quest for quality in experimental stroke research J. Cereb. Blood Flow Metab 26 , 1465-1478
31. Lee , D. S. , et al.2003) Meta-analysis of the effects of endothelin receptor blockade on survival in experimental heart failure J. Card. Fail 9 , 368-374
32. Bebarta , V. , et al.2003) Emergency medicine animal research: does use of randomization and blinding affect the results? Acad. Emerg. Med. 10 , 684-687
33. Australian Government (2004) Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 7th Edition.7 edn) (National Health and Medical Research Council, ed).
34. Organisation for Economic Co-operation and Development (2000) Guidance Document on the Recognition, Assessment and Use of Clinical Signs as Humane Endpoints. Series on Testing and Assessment Volume, 20.
35. UK Co-ordinating Committee on Cancer Research (1997) UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia (2nd Edition).
36. Kamb , A.2005) What's wrong with our cancer models? Nat. Rev. Drug Discov. 4 , 161-165
37. Sharpless , N. E. , and DePinho , R. A.2006) The mighty mouse: genetically engineered mouse models in cancer drug development Nat. Rev. Drug Discov 5 , 741-754
38. Hansen , K. , and Khanna , C.2004) Spontaneous and genetically engineered animal models; use in preclinical cancer drug development Eur. J. Cancer 40 , 858-880
39. Knapp , D. W. , and Waters , D. J.1997) Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans Mol. Med. Today 3 , 8-11
40. Khanna , C. , et al.2006) The dog as a cancer model Nat. Biotech 24 , 1065-1066
41. Pet Food Institute (2006) Pet Dog & Cat Population. Washington, DC.
42. Kimmelman , J. , and Nalbantoglu , J.2007) Faithful companions: a proposal for neurooncology trials in pet dogs Cancer Res 67 , 4541-4544
43. Tjin Tham Sjin , R. M. , et al.2006) Endostatin therapy reveals a U-shaped curve for antitumor activity Cancer Gene Ther 13 , 619-627
44. Kamstock , D. , et al.2006) Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma Cancer Gene Ther 13 , 306-317
45. Dow , S. , et al.2005) Phase I study of liposome- DNA complexes encoding the interleukin- 2 gene in dogs with osteosarcoma lung metastases Hum. Gene Ther 16 , 937-946
46. National Cancer Institute Center for Cancer Research (2006) Comparative Oncology Program. http://ccr.nci.nih.gov/resources/cop/.
47. Zabner , J. , et al.1993) Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis Cell 75 , 207-216
48. Zabner , J. , et al.1996) Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis J. Clin. Invest 97 , 1504-1511
49. Mendell , J. R. , et al.1995) Myoblast transfer in the treatment of Duchenne's muscular dystrophy N. Engl. J. Med 333 , 832-838
50. Kimmelman , J.2007) Ethics at phase 0: clarifying the issues J. Law. Med. Ethics 35 , 727-733
51. Agulnik , M. , et al.2006) Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents J. Clin. Oncol 24 , 4801-4807
52. Harrington , K. J. , et al.2005) Gene therapy for head and neck cancer Cancer Metastasis Rev 24 , 147-164
53. Penuelas , I. , et al.2005) Gene therapy imaging in patients for oncological applications Eur. J. Nucl. Med. Mol. Imaging 32 (Suppl 2) , S384 - 403
54. Iyer , M. , et al.2005) Applications of molecular imaging in cancer gene therapy Curr. Gene Ther 5 , 607-618
55. Kristian Raty , J. , et al.2007) Non-invasive Imaging in Gene Therapy Mol. Ther 15 , 1579-1586
56. Recombinant DNA Advisory Committee (RAC) (1998) Minutes of Meeting September 24-25.Department of Health and Human Services, ed), 1-50.
57. Prados , M. D. , et al.2003) Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial J. Neurooncol 65 , 269-278
58. Of course, there are likely to be exceptions. Cancer vaccines studies, for example, will have a different risk profile than those using oncolytic vectors.
59. US Food and Drug Administration, and Center for Drug Evaluation and Research (2005) Guidance for Industry on Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers.Department of Health and Human Services, ed).
60. Liu, T. -C., and Kirn, D. H.2007) Problems, Side Effects, and Disappointments in Clinical Cancer Gene Therapy. In Gene Therapy for Cancer (Cancer Drug Discovery and Development) (1st edn) (Hunt, K.K., et al., eds), 351-386, Humana Press
61. Kimmelman , J.2005) Medical research, risk, and bystanders IRB 27 , 1-6
62. Liu , S.C. , et al.2002) Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis Gene Ther 9 , 291-296
63. Sasaki , T. , et al.2006) Genetically engineered Bifidobacterium longum for tumor-targeting enzyme-prodrug therapy of autochthonous mammary tumors in rats Cancer Sci 97 , 649-657
64. Lichtenstein , D. L. , and Wold , W. S.2004) Experimental infections of humans with wildtype adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission Cancer Gene Ther 11 , 819-829
65. Kimmelman , J.2007) Missing the forest: further thoughts on the ethics of bystander risk in medical research Camb. Q. Healthcare Ethics 16 , 483-490
66. Joffe , S. , and Miller , F.G.2006) Rethinking risk-benefit assessment for phase I cancer trials J. Clin. Oncol 24 , 2987-2990
67. Agrawal , M. , and Emanuel , E. J.2003) Ethics of phase 1 oncology studies: reexamining the arguments and data JAMA 290 , 1075-1082
68. Markman , M.2006) "Therapeutic intent" in phase 1 oncology trials: a justifiable objective Arch. Intern. Med 166 , 1446-1448
69. Lidz , C. W. , and Appelbaum , P. S.2002) The therapeutic misconception: problems and solutions Med. Care 40 , V55 - 63
70. Penman , D. T. , et al.1984) Informed consent for investigational chemotherapy: patients' and physicians' perceptions J. Clin. Oncol 2 , 849-855
71. Lipsett , M. B.1982) On the nature and ethics of phase I clinical trials of cancer chemotherapies JAMA 248 , 941-942
72. Sixty-four percent expect some sort of benefit. Weinfurt, K. P., et al.2003) The correlation between patient characteristics and expecta tions of benefit from Phase I clinical trials. Cancer 98 , 166-75.
73. Horng , S. , and Grady , C.2003) Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism IRB 25 , 11-16
74. Cheng , J. D. , et al.2000) Impact of quality of life on patient expectations regarding phase I clinical trials J. Clin. Oncol 18 , 421-428
75. Kimmelman , J.2007) The therapeutic misconception at 25: treatment, research, and confusion Hastings Cent. Rep 37 , 36-42
76. Koyfman , S. A. , et al.2007) Risks and benefits associated with novel phase 1 oncology trial designs Cancer 110 , 1115-1124
77. The figure of 1% is controversial Schneiderman L. J. , Jecker N. S. , and Jonsen A. R.1990) Medical Futility: Its Meaning and Ethical Implications Ann. Intern. Med. 112 : 949-954
78. Schneiderman , L. J. , and Jecker , N. S.1995) Wrong Medicine: Doctors, Patients, and Futile Treatment John Hopkins University Press , Baltimore, MD.
79. Atkins , M. B. , et al.2004) Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma Clin. Cancer Res. 10 , 6342S - 6346S
80. Perhaps one way of summarizing the foregoing discussion is as follows: from an individual patient perspective, discussion of therapeutic benefits is not without a basis. However, from a public policy perspective, it is. Since study protocols and informed consent practices are reviewed at a policy level, it makes more sense for the policy framework to prevail in this context.
81. Kimmelman , J. , and Palmour , N.2005) Therapeutic optimism in the consent forms of phase 1 gene transfer trials: an empirical analysis J. Med. Ethics 31 , 209-214
82. Henderson , G. E. , et al.2004) Uncertain benefit: investigators' views and communications in early phase gene transfer trials Mol. Ther 10 , 225-231
83. Sankar , P.2004) Communication and miscommunication in informed consent to research Med. Anthropol. Q 18 , 429-446
84. Khuri , F. R. , et al.2000) a controlled trial of intratumoral ONYX-015, a selectivelyreplicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nat. Med 6 , 879-885
85. Sherwin , S.2005) Belmont Revisited through a Feminist Lens In Belmont Revisited: Ethical Principles for Research with Human Subjects ( Childress , J.F. , et-al. , eds), 148-164
86. Kelly , E. , and Russell , S.J.2007) History of oncolytic viruses: Genesis to genetic engineering Mol. Ther 15 , 651-659
87. Lerner , B.H.2004) Sins of omission-cancer research without informed consent N. Engl. J. Med 351 , 628-630
88. Kahn , J. P. , et al.1998) Changing Claims About Justice in Research: An Introduction and Overview In Beyond Consent: Seeking Justice in Research ( Kahn , J. P. , et al , eds), Oxford University Press , New York
89. The patient's husband was chairman of the board of the San Diego Regional Cancer Center, and he prevailed on Iowa's Senator Tom Harkin to persuade NIH to grant exemption to their usual review procedures.
90. Jenks , S.1993) RAC approves policy for single- patient use of gene therapy J. Natl. Cancer Inst 85 , 266-267
91. Lysaught , M. T.1998) Commentary: reconstruing genetic research as research J. Law. Med. Ethics 26 , 48-54
92. Einhorn, B., et al.2006) A cancer treatment you can't get here: China, with lower regulatory hurdles, is racing to a lead in gene therapy. In Bus. Week. March 6, 2006.
93. Jia , H. , and Kling , J.2006) China offers alternative gateway for experimental drugs Nat. Biotechnol 24 , 117-118
94. Council for International Organizations of Medical Sciences (CIOMS) (2002) International Ethical Guidelines for Biomedical Research Involving Human Subjects. World Health Organization.
95. National Bioethics Advisory Commission (2001) Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries. In Volume I: Report and Recommendations of the National Bioethics Advisory Commission.
96. Nuffield Council on Bioethics (2002) The Ethics of Research Related to Healthcare in Developing Countries.
97. Council for International Organizations of Medical Sciences (CIOMS) (2002) International ethical guidelines for biomedical research involving human subjects. Bull. Med. Ethics 17-23.
98. London , A. J.2005) Justice and the human development approach to international research Hastings Cent. Rep 35 , 24-37
99. Which is approximately $2700. 100 Jia , H.2006) Controversial Chinese genetherapy drug entering unfamiliar territory Nat. Rev. Drug Discov 5 , 269-270
100. Staff (2006) China's War on Cancer. In Red Herring: The Business of Technology April 29, 2006.
101. Advisory Committee on Human Radiation Experiments (1995) Final Report.
102. Kolata, G.1998) Hope in the Lab: A Special Report; A Cautious Awe Greets Drugs that Eradicate Tumors in Mice. In The New York Times , May 3, 1998; p 1.
103. Bogler , O. , and Mikkelsen , T.2003) Angiogenesis in glioma: molecular mechanisms and roadblocks to translation Cancer J 9 , 205-213
104. Ryan , D. P. , et al.1999) Reality testing in cancer treatment: the phase I trial of endostatin Oncologist 4 , 501-508
105. Snyder , L. , and Leffler , C.2005) Ethics manual: fifth edition Ann. Intern. Med 142 , 560-582
106. Indian Council of Medical Research (2006) Ethical Guidelines for Biomedical Research on Human Participants
107. Guidelines on Good Research Practice he Association of Medical Research Charities.
108. Kimmelman , J.(expected publication date) 2009) Gene Transfer and the Ethics of First in Human Experiments: Lost in Translation Cambridge University Press , New York